Revvity (RVTY) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Revvity (RVTY) quarterly earnings & revenue
Revvity (RVTY) reported revenue of $711.12M for Q1 2026, up 7.0% year-over-year, with net income of $40.72M and diluted EPS of $0.36.
Over the last four reported quarters, Revvity generated $2.90B in revenue and $240.96M in net income.
Revvity's next earnings report is scheduled for August 4, 2026 before market open; analysts estimate EPS of $1.23.
Revvity quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $711.12M | +7.0% | $40.72M | $0.36 |
| Q4 2025 | $772.06M | +5.9% | $98.36M | $0.87 |
| Q3 2025 | $698.95M | +2.2% | $46.65M | $0.40 |
| Q2 2025 | $720.28M | +4.1% | $55.22M | $0.47 |
| Q1 2025 | $664.76M | +2.3% | $42.24M | $0.34 |
| Q4 2024 | $729.37M | +4.8% | $95.04M | $0.78 |
| Q3 2024 | $684.05M | +2.0% | $93.97M | $0.76 |
| Q2 2024 | $691.68M | -2.5% | $79.11M | $0.64 |
Revvity (RVTY) — frequently asked questions
When does Revvity (RVTY) report earnings next?
Revvity is expected to report earnings on August 4, 2026 before market open. Analysts estimate EPS of $1.23.
What was RVTY's revenue last quarter?
Revvity reported revenue of $711.12M in Q1 2026, up 7.0% from the same quarter a year earlier.
What was RVTY's EPS last quarter?
Revvity reported diluted EPS of $0.36 in Q1 2026.
Is Revvity profitable?
Revvity is currently profitable, with $240.96M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)